With optimal HF treatment, compliant with the current European guidelines [38] (angiotensin receptor neprilysin inhibitor or angiotensin-converting enzyme inhibitor, beta-blocker, mineralocorticoid receptor antagonist, sodium-glucose transporter-2 inhibitor), all our patients improved clinically. This evidence concerns the gene NR3C2 and hydrops fetalis.